When: Forward EPS revision toward $10-11

Then: Sell

When: Pullback to $258-263 zone with RSI reset toward 45-50 and fresh MACD positive crossover

Then: Re-rate to Overweight

HOLD

• Price closed above prior breakout level at $275.21, not distribution—the MACD histogram turned positive as a fresh bullish trigger and Bollinger upper band was pierced intraday
• RSI is at 64, not 75, indicating the stock is not overbought; 10 EMA crossed above 50 SMA weeks ago and is now at $269, providing dynamic support nearly six dollars below the close
• Dividend has grown for 60+ consecutive years and was raised 5% this year; yield-on-cost crosses Treasury yields around year 4-5 with capital appreciation optionality
• Q2 2026 revenue was $25.3 billion (highest quarterly print in the dataset), operating margin recovered to 28.3%, and free cash flow was $7.3 billion in Q2 alone
• Pipeline (Tremfya, Darzalex, Carvykti) is already showing up in the numbers, not hypothetical
• Forward P/E of 22x with AAA balance sheet, 25.7% ROE, and beta of 0.231 represents reasonable valuation even if consensus comes in 10-20% light (25-27x P/E)
• 50 SMA at $258.72 is the hard invalidation level—stock is 6% above with momentum accelerating away
• In a no-cut regime with Fed on hold through 2026 at 89% probability and recession odds at 8%, demand for high-quality compounders intensifies as alternatives for stable cash flow narrow
• The conservative approach is to hold the full position and add on pullbacks to the 50 SMA zone if momentum remains constructive, not trim a confirmed uptrend
• JNJ in 2026 is a defensive healthcare franchise with negative beta, AAA credit, and demand inelasticity—holding through volatility is precisely what protects the portfolio

→ vs aggressive: The 'failed breakout' thesis is pattern-matching noise—the stock closed above the prior breakout level and MACD just turned positive, a fresh bullish trigger rather than confirmation of a top; real breakdowns close below the 50 SMA

→ vs aggressive: The dividend versus Treasury argument is intellectually dishonest—comparing a nominal locked Treasury yield (4.2%) to a growing annuity with 60+ years of consecutive growth (5% raise this year) is not equivalent; yield-on-cost crosses Treasury yields in year 4-5

→ vs aggressive: Forward EPS skepticism ignores actual operational reality—Q2 revenue was $25.3 billion (highest ever), operating margin recovered to 28.3%, and free cash flow was $7.3 billion; pipeline is already in the numbers

→ vs aggressive: The asymmetric risk-reward framing is wrong—the downside to 200-day MA and upside to $320 target calculation only holds if the trend is ending, but all indicators suggest the higher-probability path is higher

→ vs aggressive: The 2008 comparison is lazy and wrong—JNJ in 2026 is not a leveraged bank or subprime originator; it is a defensive healthcare franchise with negative beta, AAA credit, and inelastic demand

→ vs aggressive: Selling JNJ to redeploy into 'names with upside leverage' is market-timing dressed as risk management—if upside leverage were wanted, rotation should have happened months ago

Moderate trim of 10-15% of position; maintain core exposure with ATR-based trailing stop around $263-$264; define two re-entry triggers at $281.07 (momentum breakout) or $258.72 (value pullback to 50 SMA)

• Position has run 59% off 52-week low and sits 17% above the 200-day moving average, creating concentration risk that warrants modest trim
• ATR-based trailing stop recommended at approximately $263-$264 (above the 50 SMA at $258.72)
• Conservative analyst's hold-everything approach is itself a market call that underweights known fundamental headwinds (Stelara erosion, MedTech weakness, debt doubling, talc litigation)
• Aggressive analyst's 25-33% trim recommendation overstates the bearish case; the 59% rally is real trend evidence, not distribution
• Two defined re-entry triggers: momentum add above $281.07 close on volume, or value add at 50 SMA $258.72 pullback with constructive momentum
• Macro backdrop is a tailwind for JNJ: 89% probability of no Fed cuts in 2026, 8% recession probability falling, favoring defensive compounders with dividend reliability
• JNJ dividend has compounded for 60 consecutive years with yield-on-cost crossover around year 4-5, making Treasury yield comparison incomplete
• Aggressive analyst's Treasury-versus-dividend argument and 2008 comparison are overstatements that don't invalidate legitimate concentration concerns

→ vs aggressive: The 25-33% trim recommendation overstates the bearish case; the close was still inside the upper Bollinger band, MACD turned positive, and stock is consolidating at upper range—not a failed breakout

→ vs conservative: Never addresses what a 59%-rallied position looks like from portfolio construction standpoint; concentration risk in a name with multiple known headwinds at 52-week highs is not trivial